Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2934 - Fatigue and quality of life (QoL) during and after adjuvant treatment by trastuzumab (Herceptin®) among breast cancer patients (BC pts): a case-control study


10 Oct 2016


Poster display


Sabine Noal


Annals of Oncology (2016) 27 (6): 43-67. 10.1093/annonc/mdw364


S. Noal1, N. Heutte2, D. Allouache3, C. Delcambre3, A. Faveyrial3, C. Levy3, C. Segura3, J. Geffrelot4, C. Rieux2, A. Leconte2, B. Clarisse2

Author affiliations

  • 1 Oncology Departement, Centre Francois Baclesse, 14000 - Caen/FR
  • 2 Clinical Research Department, Centre Francois Baclesse, Caen/FR
  • 3 Oncology Department, Centre Francois Baclesse, Caen/FR
  • 4 Radiotherapy Department, Centre Francois Baclesse, Caen/FR


Abstract 2934


Trastuzumab (Herceptin®, Roche) has become a mainstay in the treatment of pts with human epidermal growth factor receptor-2 (HER2)-overexpressing breast cancer in the adjuvant setting. Trastuzumab treatment consists in 21-day cycles during the last 3 cycles of FEC100-Docetaxel chemotherapy (CT) and 15 additional cycles thereafter. Although adjuvant CT was shown to have a deleterious effect on QoL and fatigue in BC pts, no data are available on experience of BC pts during this additional one-year treatment period by Trastuzumab. This case-control study assessed fatigue and QoL during and after Trastuzumab treatment as compared to age-matched BC pts receiving the same CT without Trastuzumab.


70 pts were included (35 pts in each group) on day 1 of last cycle of CT (first day of Trastuzumab for case group). The primary endpoint was severe fatigue (FACIT-F 


No statistically significant differences were noted at baseline between groups: age (48 ± 10 y); marital status (87%); surgery (mastectomy, 42%); CT (all pts received complete FEC100-Docetaxel treatment except one pt who received only 1 cycle of Docetaxel; dose reduction for 12 pts); radiotherapy (84%); hormonotherapy (69%); anxiety (41%); depression (23%); severe fatigue at baseline (66%). At 9 mo post CT, proportion of pts with severe fatigue (39%) did not statistically significantly differ between groups and a significant reduction of severe fatigue from baseline was noted (p 


Trastuzumab treatment was not shown to have a deleterious impact on fatigue and QoL in adjuvant setting as compared to CT with no indication to Trastuzumab treatment. CT-induced fatigue appears to improve similarly between women receiving or not Trastuzumab, despite a one-year longer duration of treatment.

Clinical trial identification

Clinical trial information: NCT01400438

Legal entity responsible for the study



Ligue contre le Cancer and Association “Le Cancer du Sein, Parlons-En !”, c/o Estée Lauder - Prix Ruban Rose


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings